CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 79 enrolled
Drug / intervention
FPA144drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02318329
NCT02318329Phase 1Completed
CompareCT.gov

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Five Prime Therapeutics, Inc.·interventional·Posted Dec 17, 2014·Updated Jun 4, 2024

In Brief

A Phase 1 clinical trial evaluating FPA144 for Advanced Solid Tumors and 2 related conditions. Completed, enrolled 79 participants across 26 sites in 3 countries.

Detailed Summary

This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
CountriesSouth Korea, Taiwan, United States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 17, 2014
Enrollment StartNov 1, 2014
Primary CompletionFeb 28, 2019
Study CompletionJun 30, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.5 years ago

Interventions

FPA144drug

FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.